A. Hobisch

发表

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

H. Klocker, G. Bartsch, W. Horninger, 1998, Cancer research.

Androgen receptors in prostate cancer.

H. Klocker, G. Bartsch, A. Hobisch, 2003, Endocrine-related cancer.

Androgen receptors in prostate cancer.

H. Klocker, G. Bartsch, A. Hobisch, 2002, The Journal of urology.

Interleukin‐6 regulation of prostate cancer cell growth

Georg Bartsch, Hannes Steiner, G. Bartsch, 2005, Journal of cellular biochemistry.

Subclinical microtraumatisation of the scrotal contents in extreme mountain biking

L. Pallwein, F. Frauscher, A. Stenzl, 2000, The Lancet.

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

A. Hobisch, Z. Culig, H. Erb, 2012, Endocrine-related cancer.

Abstract B237: Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

A. Hobisch, Z. Culig, H. Erb, 2011 .

Androgen deprivation increases p300 expression in prostate cancer cells.

D. Tindall, T. Sebo, Kevin M. Regan, 2007, Cancer research.

Dendritic cells for the immunotherapy of renal cell carcinoma.

H. Klocker, G. Bartsch, N. Romani, 1997, Urologia internationalis.

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.

H. Klocker, G. Bartsch, M. Cronauer, 1995, European urology.

Synergistic activation of androgen receptor by androgen and luteinizing hormone‐releasing hormone in prostatic carcinoma cells

H. Klocker, G. Bartsch, M. Cronauer, 1997, The Prostate.

Activation of the androgen receptor by polypeptide growth factors and cellular regulators

H. Klocker, G. Bartsch, M. Cronauer, 2004, World Journal of Urology.

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

D. Fuchs, A. Hobisch, Z. Culig, 2007, Oncogene.

Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.

D. Fuchs, G. Bartsch, A. Berger, 2003, The American journal of pathology.

Androgen receptor – an update of mechanisms of action in prostate cancer

H. Klocker, G. Bartsch, A. Hobisch, 2000, Urological Research.

Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

H. Klocker, G. Bartsch, M. Cronauer, 1993, Molecular endocrinology.

Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience.

G. Bartsch, A. Berger, A. Hobisch, 2004, Urology.

Increased resistance to trail‐induced apoptosis in prostate cancer cells selected in the presence of bicalutamide

M. Mitterberger, A. Hobisch, Z. Culig, 2007, The Prostate.

The androgen receptor pathway is by‐passed in prostate cancer cells generated after prolonged treatment with bicalutamide

G. Bartsch, A. Hobisch, Z. Culig, 2006, The Prostate.

Expression and function of androgen receptor coactivators in prostate cancer

G. Bartsch, A. Hobisch, Z. Culig, 2004, The Journal of Steroid Biochemistry and Molecular Biology.

Retroperitoneal lymphadenectomy for clinical stage I nonseminomatous testicular tumor: laparoscopy versus open surgery and impact of learning curve.

G. Bartsch, A. Hobisch, G. Janetschek, 1996, The Journal of urology.

Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue

H. Klocker, D. Fuchs, G. Bartsch, 2000, The Journal of pathology.

An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.

G. Bartsch, H. Lilja, A. Bjartell, 2004, European journal of cancer.

Photodynamic Diagnosis with 5–Aminolevulinic Acid in the Treatment of Secondary Urethral Tumors: First in vitro and in vivo Results

H. Klocker, G. Bartsch, A. Stenzl, 2001, European Urology.

Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.

H. Klocker, G. Bartsch, M. Cronauer, 1998, British Journal of Cancer.

CD30 expression in seminoma.

G. Mikuz, A. Hobisch, H. Feichtinger, 1996, Human pathology.

Tumorigenesis and Neoplastic Progression Suppressor of Cytokine Signaling-3 Antagonizes cAMP Effects on Proliferation and Apoptosis and Is Expressed in Human Prostate Cancer

G. Bartsch, F. Offner, A. Hobisch, 2006 .

Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

L. Kenner, M. Susani, A. Hobisch, 2009, The American journal of pathology.

Interleukin‐6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase

D. Fuchs, G. Bartsch, K. Friedbichler, 2005, The Prostate.

Treatment options in localised and metastatic renal cell carcinoma

A. Hobisch, A. Berger, 2008 .

Analysis of a Mutant Androgen Receptor Offers a Treatment Modality in a Patient with Partial Androgen Insensitivity Syndrome

H. Klocker, G. Bartsch, A. Hobisch, 1998, European Urology.

Oligomeric proanthocyanidin complexes (OPC) exert anti‐proliferative and pro‐apoptotic effects on prostate cancer cells

A. Hobisch, Z. Culig, M. Puhr, 2008, The Prostate.

Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for stage IIB nonseminomatous testicular carcinoma.

G. Bartsch, A. Hobisch, G. Janetschek, 1999, The Journal of urology.

Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma.

H. Klocker, G. Bartsch, M. Cronauer, 1996, The Journal of urology.

Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas.

H. Klocker, G. Bartsch, M. Cronauer, 1997, British Journal of Cancer.

Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate

H. Klocker, G. Bartsch, M. Cronauer, 1997, The Prostate.

Antagonist/Agonist Balance of the Nonsteroidal Antiandrogen Bicalutamide (Casodex) in a New Prostate Cancer Model

H. Klocker, G. Bartsch, J. Hoffmann, 2000, Urologia Internationalis.

Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell‐specific markers

H. Klocker, G. Bartsch, M. Cronauer, 1997, The Prostate.

Expression, structure, and function of androgen receptor in advanced prostatic carcinoma

H. Klocker, G. Bartsch, A. Hobisch, 1998, The Prostate.

Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors

H. Klocker, G. Bartsch, G. Daxenbichler, 1997, The Journal of pathology.

H. Klocker, G. Bartsch, A. Hobisch, 2002 .

Androgen Receptor Mutations in Carcinoma of the Prostate

H. Klocker, G. Bartsch, A. Hobisch, 2001, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts?

H. Klocker, G. Bartsch, A. Hobisch, 1997, Histology and histopathology.

Androgen Receptor Gene Mutations in Prostate Cancer

H. Klocker, G. Bartsch, M. Cronauer, 1997, Drugs & aging.

Androgen receptor alterations in prostatic carcinoma

H. Klocker, G. Bartsch, A. Hobisch, 1994, The Prostate.

Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells

H. Klocker, G. Bartsch, M. Cronauer, 1999, British Journal of Cancer.

Mutant androgen receptors in prostatic tumors distinguish between amino‐acid‐sequence requirements for transactivation and ligand binding

H. Klocker, G. Bartsch, A. Hobisch, 1995, International journal of cancer.

Androgen Receptor and Interleukin-6 Signaling In PCA Progression

G. Bartsch, A. Hobisch, Z. Culig, 2005 .

Review Article ANDROGEN RECEPTORS IN PROSTATE CANCER

H. Klocker, G. Bartsch, A. Hobisch, 2003 .

Expression and function of androgen receptor in carcinoma of the prostate

H. Klocker, G. Bartsch, A. Hobisch, 2000, Microscopy research and technique.

Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma

H. Klocker, I. Pastan, G. Bartsch, 1998, The Prostate.

Distant MÃ © tastasesfrom Prostatic Carcinoma Express Androgen Receptor Protein 1

H. Klocker, A. Hobisch, Z. Culig, 2006 .

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

H. Klocker, G. Bartsch, M. Cronauer, 1994, Cancer research.

Androgen receptor status of lymph node metastases from prostate cancer

H. Klocker, G. Bartsch, A. Hobisch, 1996, The Prostate.

Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells

H. Klocker, G. Bartsch, M. Cronauer, 1996, The Prostate.

Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma

F. Aigner, A. Berger, A. Hobisch, 2011, BJU international.

Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results.

G. Bartsch, A. Berger, A. Hobisch, 2003, Urology.

Dendritic antigen‐presenting cells from the peripheral blood of renal‐cell‐carcinoma patients

H. Klocker, G. Bartsch, A. Hobisch, 1995, International journal of cancer.

Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study.

G. Bartsch, A. Berger, A. Hobisch, 2002, Urology.

Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate.

H. Klocker, D. Fuchs, G. Bartsch, 2000, The Journal of urology.

Metastatic spermatocytic seminoma--an extremely rare disease.

G. Bartsch, G. Mikuz, I. Verdorfer, 2006, European urology.

Experience of more than 150 laparoscopic retroperitoneal lymph node dissections of testicular tumours - technique and results

G. Bartsch, A. Hobisch, G. Janetschek, 2002 .

Primary lymphatic metastatic spread in testicular cancer occurs ventral to the lumbar vessels.

G. Bartsch, A. Hobisch, G. Janetschek, 2002, Urology.

Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome.

G. Bartsch, A. Hobisch, G. Janetschek, 2000, The Journal of urology.

Laparoscopic retroperitoneal lymph node dissection.

G. Bartsch, A. Hobisch, G. Janetschek, 2000, Urology.

Studies on androgen receptor mutations and amplification in human prostate cancer.

H. Klocker, G. Bartsch, A. Hobisch, 2003, Methods in molecular medicine.

Tumor‐infiltrating T lymphocytes from renal‐cell carcinoma express B7‐1 (CD80): T‐Cell expansion by T‐T cell co‐stimulation

H. Klocker, N. Romani, A. Hobisch, 1995, International journal of cancer.

A reliable system for the culture of human prostatic cells

H. Klocker, G. Bartsch, M. Cronauer, 1997, In Vitro Cellular & Developmental Biology - Animal.

Tumorigenesis and Neoplastic Progression Suppressor of Cytokine Signaling ( SOCS )-1 Is Expressed in Human Prostate Cancer and Exerts Growth-Inhibitory Function through Down-Regulation of Cyclins and Cyclin-Dependent Kinases

L. Kenner, M. Susani, A. Hobisch, 2010 .

Cytogenetic characterization of 22 human renal cell tumors in relation to a histopathological classification.

G. Bartsch, G. Utermann, I. Verdorfer, 1999, Cancer genetics and cytogenetics.

Characterisation of a collecting duct carcinoma by cytogenetic analysis and comparative genomic hybridisation.

G. Bartsch, I. Verdorfer, A. Hobisch, 1998, International journal of oncology.

Life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion.

G. Bartsch, G. Kemmler, A. Stenzl, 2001, Seminars in urologic oncology.

Androgen signal transduction and prostatic carcinoma

H. Klocker, G. Bartsch, A. Hobisch, 2004, World Journal of Urology.

Modified Retroperitoneal Lymph Node Dissection for Testicular Tumour: Open and Laparoscopic Approach, Operative Technique and Results

G. Bartsch, W. Horninger, A. Hobisch, 1994 .

Mechanism of Androgen Receptor Activation and Possible Implications for Chemoprevention Trials

H. Klocker, G. Bartsch, I. Eder, 1999, European Urology.

Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular tumor.

G. Bartsch, A. Hobisch, G. Janetschek, 1994, Urology.

Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.

G. Bartsch, A. Hobisch, Z. Culig, 2005, Endocrine-related cancer.

The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.

H. Klocker, G. Bartsch, A. Hobisch, 2003, The American journal of pathology.

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

Martin R. Schneider, H. Klocker, G. Bartsch, 1999, British Journal of Cancer.

Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.

G. Bartsch, A. Hobisch, Z. Culig, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Regulation of prostatic growth and function by peptide growth factors

H. Klocker, G. Bartsch, M. Cronauer, 1996, The Prostate.

Role of IL-6 in Regulating the Androgen Receptor

A. Hobisch, Z. Culig, 2009 .

Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.

H. Klocker, D. Fuchs, G. Bartsch, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Distant metastases from prostatic carcinoma express androgen receptor protein.

H. Klocker, G. Bartsch, A. Hobisch, 1995, Cancer research.

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

Dietmar Fuchs, Hannes Steiner, D. Fuchs, 2008, Endocrine-related cancer.

Metastatic spermatocytic seminoma--an extremely rare disease: Part 2.

G. Bartsch, G. Mikuz, I. Verdorfer, 2006, European urology.

Carcinoma in situ of the testis detected by DNA flow cytometry of testicular fine-needle aspirates.

G. Mikuz, A. Hobisch, H. Feichtinger, 1994, Cytometry.

New directions in endocrine therapy: renewed interest in the androgen receptor

A. Hobisch, Z. Culig, 2008 .

The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer

Georg Bartsch, G. Bartsch, F. Offner, 2004, The Journal of pathology.

Interleukin-6 and prostate cancer progression.

E. Keller, A. Hobisch, Z. Culig, 2001, Cytokine & growth factor reviews.

Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.

H. Klocker, G. Bartsch, A. Gast, 1996, Cancer detection and prevention.

Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.

L. Kenner, M. Susani, A. Hobisch, 2009, Cancer research.

Fibroblast Growth Factors and Their Receptors in Metastases of Prostate and Other Urological Cancers

H. Klocker, G. Bartsch, M. Cronauer, 2001 .

Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.

H. Klocker, G. Bartsch, W. Horninger, 2001, The Journal of urology.

Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth

G. Bartsch, A. Hobisch, Z. Culig, 2002, Molecular and Cellular Endocrinology.

Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328

J. Bektic, A. Berger, A. Hobisch, 2006, The Prostate.

Single institution experience with the transobturator sling suspension system AdVance® in the treatment of male urinary incontinence: mid-term results.

A. Berger, A. Hobisch, C. Seitz, 2011, International braz j urol : official journal of the Brazilian Society of Urology.

489 The AdVance ® sling system : Mid-Term Results sling in 26 men with stress urinary incontinence after prostate surgery with and without radiation therapy

A. Berger, A. Hobisch, C. Seitz, 2011 .

Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA‐based screening

H. Klocker, G. Bartsch, W. Horninger, 1999, The Prostate.

Posttraumatic high-flow priapism in children: noninvasive treatment by color Doppler ultrasound-guided perineal compression.

A. Hobisch, H. Volgger, S. Pfefferkorn, 2007, Urology.

DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction

H. Klocker, G. Bartsch, M. Cronauer, 1993, The Prostate.

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.

A. Hobisch, Z. Culig, M. Puhr, 2010, Endocrine-related cancer.

Detection and clinical outcome of urinary bladder cancer with 5‐aminolevulinic acid‐induced fluorescence cystoscopy

U. Pichlmeier, A. Stenzl, M. Burger, 2011, Cancer.

Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion

G. Bartsch, G. Kemmler, A. Stenzl, 2000, World Journal of Urology.

Laparoscopic retroperitoneal lymph node dissection: description of the nerve-sparing technique.

G. Bartsch, M. Gettman, A. Hobisch, 2002, Urology.

Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer.

G. Bartsch, F. Offner, A. Hobisch, 2006, The American journal of pathology.

Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion.

M. Mitterberger, A. Hobisch, Z. Culig, 2007, Endocrine-related cancer.

Androgen receptor mutations in prostate cancer

H. Klocker, G. Bartsch, A. Hobisch, 1998 .

Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial

U. Pichlmeier, A. Stenzl, M. Burger, 2011 .

Modified retroperitoneal lymphadenectomy for testicular tumor: anatomical approach, operative technique and results.

G. Bartsch, W. Horninger, A. Hobisch, 1993, European Urology.

Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma.

A. Hobisch, Z. Culig, M. Zaki, 2008, Advances in experimental medicine and biology.

Occurrence of polyorchidism in a young man.

G. Bartsch, A. Berger, A. Hobisch, 2002, Urology.

Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression

G. Bartsch, E. Artner-Dworzak, A. Hobisch, 2004, The Prostate.

1085: Transurethral Detection and Resection of Bladder Carcinomas Under White or 5-ALA Induced Fluorescence Light: Results of the First Double-Blind-Placebo Controlled Clinical Trial

Michael Scholz, Arnulf Stenzl, Hannes Steiner, 2007 .

Late penile metastasis from primary bladder carcinoma.

G. Bartsch, A. Berger, A. Hobisch, 2003, Urology.

VI--choosing the right reconstruction for your female patients.

G. Bartsch, A. Stenzl, H. Strasser, 2001, Seminars in urologic oncology.

Laparoscopic retroperitoneal lymph node dissection.

G. Bartsch, A. Hobisch, G. Janetschek, 2000, Journal of endourology.

Androgen Receptor Crosstalk with Cell Signaling Pathways

H. Klocker, G. Bartsch, A. Hobisch, 2003 .

Antiandrogens in prostate cancer endocrine therapy.

G. Bartsch, A. Hobisch, Z. Culig, 2004, Current cancer drug targets.

Laparoscopic retroperitoneal lymph node dissection.

A. Hobisch, G. Janetschek, R. Peschel, 2001, Journal of endourology.

Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma.

H. Klocker, G. Bartsch, M. Cronauer, 1996, The Journal of urology.

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

H. Klocker, J. Trapman, A. Hobisch, 1994, Cancer Research.

Clinical value of fructose 1,6 bisphosphatase in monitoring renal proximal tubular injury.

W. Pfaller, M. Nevinny-Stickel, M. Joannidis, 1994, Kidney international. Supplement.

[Laparoscopic retroperitoneal lymph node excision in clinical stage I non-seminomatous testicular cancer].

G. Bartsch, A. Hobisch, G. Janetschek, 1994, Der Urologe. Ausg. A.